CytoDyn Inc. Form 4 (Sept. 6, 2022) — Urbach Tanya Durkee

Summary

A Form 4 for CytoDyn Inc. [CYDY] reports option grants to director Urbach Tanya Durkee, who also holds 162,113 shares of common stock directly. On September 6, 2022, the reporting person acquired non-qualified stock options (right to buy) at an exercise price of $0.5 expiring September 6, 2032: one grant of 112,500 options exercisable September 6, 2022, and one of 247,111 options. The explanation states that as of August 31, 2022, 61,777 shares have vested and the balance will vest in nine equal monthly installments beginning on September 1, 2022, subject to Continuous Service. Antonio Migliarese signed /s/ as Attorney-In-Fact on September 8, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Urbach Tanya Durkee (Last) (First) (Middle) 1111 MAIN STREET, SUITE 660 (Street) VANCOUVER WA 98660 (City) (State) (Zip) | Urbach Tanya Durkee | (Last) | (First) | (Middle) | 1111 MAIN STREET, SUITE 660 | VANCOUVER | WA | 98660 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [ CYDY ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 09/06/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 162,113 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Non-qualified stock option (right to buy) | $ 0.5 | 09/06/2022 | A | 112,500 | 09/06/2022 | 09/06/2032 | Common Stock | 112,500 | $ 0 | 112,500 | D
Non-qualified stock option (right to buy) | $ 0.5 | 09/06/2022 | A | 247,111 | (1) | 09/06/2032 | Common Stock | 247,111 | $ 0 | 241,111 | D
Explanation of Responses:
1. As of August 31, 2022, 61,777 shares have vested; the balance will vest in nine equal monthly installments beginning on September 1, 2022, subject to Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date.
/s/ Antonio Migliarese, Attorney-In-Fact | 09/08/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_CYDY_4_filed2022-09-08_0001104659-22-098628.xml

Size

16,979 bytes

SHA-256

7019d515b7ade4f1a697d0485b296ea8ee2ce399c2890de14efc1a1d078060dd

Our copy

SEC_CYDY_4_filed2022-09-08_0001104659-22-098628.xml

Original

www.sec.gov